These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 36472472)

  • 21. Bispecific antibodies for cancer therapy: the light at the end of the tunnel?
    Chames P; Baty D
    MAbs; 2009; 1(6):539-47. PubMed ID: 20073127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alternative molecular formats and therapeutic applications for bispecific antibodies.
    Spiess C; Zhai Q; Carter PJ
    Mol Immunol; 2015 Oct; 67(2 Pt A):95-106. PubMed ID: 25637431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COVID-19 treatments approved in the European Union and clinical recommendations for the management of non-hospitalized and hospitalized patients.
    Bellino S
    Ann Med; 2022 Dec; 54(1):2856-2860. PubMed ID: 36259490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Teclistamab: First Approval.
    Kang C
    Drugs; 2022 Nov; 82(16):1613-1619. PubMed ID: 36352205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody Engineering & Therapeutics 2015: The Antibody Society's annual meeting December 7-10, 2015, San Diego, CA.
    Parren PW; Burton DR; Bradbury A; Huston JS; Carter PJ; Veldman T; Chester KA; Larrick JW; Alfenito MR; Scott JK; Weiner LM; Adams GP; Reichert JM
    MAbs; 2015; 7(6):981-8. PubMed ID: 26421752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interference in a Neutralizing Antibody Assay for Odronextamab, a CD20xCD3 Bispecific mAb, from Prior Rituximab Therapy and Possible Mitigation Strategy.
    Irvin SC; D'Orvilliers A; Bloch N; Boccio K; Pennucci J; Brouwer-Visser J; Ullman E; Rajadhyaksha M; Hassanein M; Potocky T; Torri A; Hermann A; Partridge MA
    AAPS J; 2022 Jun; 24(4):76. PubMed ID: 35725847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibodies to watch in 2013: Mid-year update.
    Reichert JM
    MAbs; 2013; 5(4):513-7. PubMed ID: 23727858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coming-of-Age of Antibodies in Cancer Therapeutics.
    Ayyar BV; Arora S; O'Kennedy R
    Trends Pharmacol Sci; 2016 Dec; 37(12):1009-1028. PubMed ID: 27745709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protective measures against Omicron could be more effective than Evusheld® in liver transplant recipients.
    Odriozola Herrán A; Fortea Ormaechea JI; Cuadrado A; Puente Sánchez Á; Lazarus JV; Crespo J; Fábrega E
    Rev Esp Enferm Dig; 2022 Dec; 114(12):769-770. PubMed ID: 36043545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.
    Montgomery H; Hobbs FDR; Padilla F; Arbetter D; Templeton A; Seegobin S; Kim K; Campos JAS; Arends RH; Brodek BH; Brooks D; Garbes P; Jimenez J; Koh GCKW; Padilla KW; Streicher K; Viani RM; Alagappan V; Pangalos MN; Esser MT;
    Lancet Respir Med; 2022 Oct; 10(10):985-996. PubMed ID: 35688164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review.
    Ustianowski A
    Expert Rev Anti Infect Ther; 2022 Dec; 20(12):1517-1527. PubMed ID: 36217836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mosunetuzumab: First Approval.
    Kang C
    Drugs; 2022 Jul; 82(11):1229-1234. PubMed ID: 35947358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COVID-19 vaccine associated transverse myelitis-Evusheld as an option when vaccination is not recommended due to severe adverse events.
    Fitzsimmons WE
    Hum Vaccin Immunother; 2022 Nov; 18(5):2068338. PubMed ID: 35511579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses.
    Woopen C; Konofalska U; Akgün K; Ziemssen T
    Front Immunol; 2022; 13():897748. PubMed ID: 35958567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Next Generation Antibody Therapeutics Using Bispecific Antibody Technology].
    Igawa T
    Yakugaku Zasshi; 2017; 137(7):831-836. PubMed ID: 28674296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 8(th) Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland.
    Beck A; Carter PJ; Gerber HP; Lugovskoy AA; Wurch T; Junutula JR; Kontermann RE; Mabry R
    MAbs; 2013; 5(3):339-57. PubMed ID: 23493119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. COVID-19 update: Dosing interval for tixagevimab/cilgavimab (Evusheld).
    Med Lett Drugs Ther; 2022 Aug; 64(1656):e122-e123. PubMed ID: 35921074
    [No Abstract]   [Full Text] [Related]  

  • 39. Monoclonal antibody: the corner stone of modern biotherapeutics.
    Xia ZN; Cai XT; Cao P
    Yao Xue Xue Bao; 2012 Oct; 47(10):1275-80. PubMed ID: 23289138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
    Vincent KJ; Zurini M
    Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.